Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
Status:
Withdrawn
Trial end date:
2022-11-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well donor cellular therapy after cytarabine works in
treating patients with intermediate-risk acute myeloid leukemia with a decrease in or
disappearance of signs and symptoms of cancer. Donor cellular therapy is a short-term
transfusion of cells from a family member who is incompletely matched. The use of these
partially matched white blood cells may help improve response to standard chemotherapy
(cytarabine) and reduce some of the risks of infection, without a permanent transplant. Drugs
used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving donor cellular therapy after cytarabine may kill more cancer cells.